Answers are grounded in this paper and cite their sources.
Demonstrates improved survival in tumors with ALOX12B alterations, suggesting a predictive biomarker for ICIs.
e14546 Background: ALOX12B encodes 12R-lipoxygenase (12R-LOX), an arachidonic-acidlipoxygenase that generates fatty-acid hydroperoxides and downstream lipid signalingintermediates. Arachidonic-acid–derived lipid mediators can shape antitumor immunity bymodulating myeloid and T-cell programs within the tumor microenvironment. As a result LOX-pathway perturbations may influence ICIsensitivity. Despite this rationale, the relevance of ALOX12B to antitumor immunity and ICIoutcomes has not been systematically defined. We therefore tested whether ALOX12Balterations identify a subgroup with enhanced clinical benefit from ICI therapy. Methods: In cBioPortal’s “TMB and Immunotherapy (MSK, Nat Genet 2019)” cohort, tumorswere grouped as ALOX12B-altered (n = 24; mutations/structural variants) or unaltered(n = 1,637). Non-synonymous tumor mutation burden (mut/Mb) was compared betweengroups. Overall survival (OS) from ICI initiation was assessed by Kaplan–Meier and log-rank ,subtypes including melanoma and colorectal cancer (CRC) subsets. Co-alterations weresummarized. TIMER3 Mutation and Immunotherapy_outcome modules were used fororthogonal immune-infiltration and independent ICI outcome support. Results: ALOX12B alterations occurred in 24/1,661, enriched in melanoma (12/24) and CRC(4/24). Altered tumors had markedly higher TMB (median 43.37 vs 5.87 mut/Mb; p = 1.72×10^-9).Overall survival (OS, months) favored ALOX12B-altered tumors across cancers (median58.0 vs 18.0 months; p = 0.036), in melanoma ( 58.0 vs 42.0 months; p = 0.204), and in CRC(median not reached vs 15.0 months; p = 0.0309). Most Frequent co-alterations includedTERT (67%) and EPAS1 (60%). TIMER3 Mutation-module analysis linked ALOX12B mutation to higher T-cell–relatedinfiltration signatures—particularly CD8+ and cytotoxic/exhausted T-cell programs—acrossmultiple deconvolution methods, including ImmuCellAI, xCell, ABIS, CIBERSORT-ABS,quanTIseq, and the TIMER algorithm (nominal p<0.05).In the TIMER3Immunotherapy_outcome module, higher ALOX12B expression was associated with bettersurvival after ICI treatment in glioblastoma patients (GBM_PRJNA482620; Cox coefficient =−2.11, p = 0.035). Conclusions: ALOX12B alterations define a rare, hypermutated subgroup with improved survivalfollowing immune checkpoint inhibition. Across complementary analyses, ALOX12B-altered tumors demonstrate a strong TMB signal and supportive immune-contexture features, includingCD8/Treg-related infiltration indicators, together suggesting that ALOX12B status may serve asa robust biomarker of ICI benefit. These findings warrant deeper mechanistic study andvalidation in larger, tumor-specific immunotherapy datasets with multivariable modeling toconfirm independent predictive value and establish clinical applicability.
No takes yet. Share an insight, caveat, or question.
Amer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: